Menü
sharewise sharewise
Einloggen
Registrieren
Einloggen
Registrieren
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Eine neu veröffentlichte multizentrische RCT zeigt, dass Smith+Nephew PICO◊ sNPWT kanisterlose Unterdruck-Wundtherapie herkömmlicher tNPWT bei der Reduzierung von Wundfläche, -tiefe und -volumen bei DFU und UCV überlegen ist
Eine neu veröffentlichte multizentrische RCT zeigt, dass Smith+Nephew PICO◊ sNPWT kanisterlose Unterdruck-Wundtherapie herkömmlicher tNPWT bei der Reduzierung von Wundfläche, -tiefe und -volumen bei DFU und UCV überlegen ist


Smith+Nephew (LSE:SN, NYSE:SNN), das globale Medizintechnikunternehmen, freut sich, die Veröffentlichung von Ergebnissen aus einer neuen randomisierten kontrollierten klinischen Studie (RCT)

BusinessWire_DE 
0 23.01.20
Clinical trial demonstrated superior wound closure rates with PICO◊ compared to traditional NPWT in lower extremity ulcers1
Clinical trial demonstrated superior wound closure rates with PICO◊ compared to traditional NPWT in lower extremity ulcers1


Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the publication of a new randomized controlled trial (RCT) which demonstrated that the use of PICO Single

BusinessWire_EN 
0 16.01.20
 Clinigen and Orphazyme launch an Early Access Program for arimoclomol in patients with Niemann-Pick disease type C
 Clinigen and Orphazyme launch an Early Access Program for arimoclomol in patients with Niemann-Pick disease type C


Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has partnered with Orphazyme A/S (ORPHA.CO, ‘Orphazyme’), a global biopharmaceutical company dedicated to

BusinessWire_EN 
0 06.01.20
Amarin: Vorzeitige Bescherung durch die FDA!
Amarin: Vorzeitige Bescherung durch die FDA!

Am vergangenen Freitag, dem 13. Dezember, war die Aktie von Amarin (WKN: A0NBNG) in den USA den größten Teil des Tages vom Handel ausgesetzt. Grund hierfür war eine bevorstehende, Kurs bewegende

sharedeals 
0 16.12.19
LivaNova to Present New Data on Vagus Nerve Stimulation Therapy System at the American Epilepsy Society 2019 Annual Meeting
LivaNova to Present New Data on Vagus Nerve Stimulation Therapy System at the American Epilepsy Society 2019 Annual Meeting


LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it will present new registry data from two patient populations benefiting from Vagus Nerve

BusinessWire_EN 
0 05.12.19
LivaNova to Restructure its Heart Valve Business Line and End Caisson Transcatheter Mitral Valve Replacement Program
LivaNova to Restructure its Heart Valve Business Line and End Caisson Transcatheter Mitral Valve Replacement Program


LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it is ending its Caisson Transcatheter Mitral Valve Replacement (TMVR) program and will

BusinessWire_EN 
0 20.11.19
LivaNova restrukturiert sein Geschäftsgebiet Herzklappen und beendet das Programm zum Austausch von Mitralklappen mit Caisson-Transkathetern
LivaNova restrukturiert sein Geschäftsgebiet Herzklappen und beendet das Programm zum Austausch von Mitralklappen mit Caisson-Transkathetern


LivaNova PLC (NASDAQ:LIVN), ein marktführendes Unternehmen der Medizintechnik und Innovation, gab heute bekannt, dass es sein Programm Caisson Transcatheter Mitral Valve Replacement (TMVR) beendet

BusinessWire_DE 
0 20.11.19
LivaNova to Present at the Berenberg and Piper Jaffray Conferences
LivaNova to Present at the Berenberg and Piper Jaffray Conferences


LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Thad Huston, Chief Financial Officer, will participate in discussions at the Berenberg European Conference

BusinessWire_EN 
0 19.11.19
Amarin: 16:0-Kantersieg beim gestrigen FDA-Meeting
Amarin: 16:0-Kantersieg beim gestrigen FDA-Meeting

Die Aktie des irisch-amerikanischen Biotechunternehmens Amarin (WKN: A0NBNG) ist schon seit einiger Zeit vom Handel ausgesetzt. Grund für diese Handelsaussetzung war das angekündigte Treffen von

sharedeals 
0 15.11.19
Amarin: 16:0-Kantersieg bei FDA-Meeting
Amarin: 16:0-Kantersieg bei FDA-Meeting

Die Aktie des irisch-amerikanischen Biotechunternehmens Amarin (WKN: A0NBNG) ist schon seit einiger Zeit vom Handel ausgesetzt. Grund für diese Handelsaussetzung war das angekündigte Treffen von

sharedeals 
0 15.11.19
LivaNova Honors Epilepsy Awareness Month
LivaNova Honors Epilepsy Awareness Month


LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, honors National Epilepsy Awareness Month in the United States this November. The company is working to bring

BusinessWire_EN 
0 08.11.19
2018's 3 Biggest Catalysts for Marijuana Stocks
2018's 3 Biggest Catalysts for Marijuana Stocks
Forget seeing marijuana stocks go up in smoke in 2017. They've been smoking hot.According to cannabis research firm ArcView, the North American legal weed industry is expected to grow by 26% a....
TheMotleyFool 
0 22.12.17
3 Best Marijuana Biotech Stocks for 2018
3 Best Marijuana Biotech Stocks for 2018
Next year should be enormously important for Canadian marijuana stocks, as the country moves forward with legalization of recreational marijuana. But that milestone means little for biotechs....
TheMotleyFool 
0 22.12.17
3 High-Yield Stocks Still Worth Buying
3 High-Yield Stocks Still Worth Buying
Who doesn't like free money? While they may be somewhat forgotten as the stock market hits seemingly one new high after another, high-yield dividend stocks play an important role in providing....
TheMotleyFool 
0 19.12.17
The 3 Marijuana Stocks With the Most Cash on Their Balance Sheets
The 3 Marijuana Stocks With the Most Cash on Their Balance Sheets
There aren't too many industries that can hold a candle to the returns of cryptocurrencies these days, but the marijuana industry isn't going down without a fight. Marijuana stocks certainly have....
TheMotleyFool 
0 11.12.17
Why Entellus Medical Inc. Skyrocketed Higher Today
Why Entellus Medical Inc. Skyrocketed Higher Today
Entellus Medical (NASDAQ: ENTL) is up 50% at 12:33 p.m. EST after announcing that it's being acquired by Stryker (NYSE: SYK) for $24 per share.Stryker's investors seem to think the deal is just....
TheMotleyFool 
0 07.12.17
Here's What Caused This Marijuana Stock to Skyrocket 15% in November
Here's What Caused This Marijuana Stock to Skyrocket 15% in November
Medical marijuana has been used to treat epilepsy in patients for years, but so far, it's efficacy and safety hasn't been supported by a regulatory green light from the Food and Drug....
TheMotleyFool 
0 07.12.17
5 Key Things to Know About This Leading Marijuana Stock's Future
5 Key Things to Know About This Leading Marijuana Stock's Future
You can count the number of pure-play marijuana stocks with a market cap of around $3 billion on one hand -- and have several fingers left over. GW Pharmaceuticals (NASDAQ: GWPH) ranks as one of....
TheMotleyFool 
0 06.12.17
Is a Dividend Cut Coming From GlaxoSmithKline plc?
Is a Dividend Cut Coming From GlaxoSmithKline plc?
One of the attractions of investing in British drugmaker GlaxoSmithKline plc (NYSE: GSK) is its generous dividend yield, which lately has hovered at just a bit less than 6%. A yield that's so far....
TheMotleyFool 
0 02.12.17
This Marijuana Stock Is Poised for a Breakout Year in 2018 -- Here's What You'll Want to Know About It
This Marijuana Stock Is Poised for a Breakout Year in 2018 -- Here's What You'll Want to Know About It
Admittedly, 2017 so far has kind of been a ho-hum year for former high-flying marijuana stock GW Pharmaceuticals (NASDAQ: GWPH). For the most part, investors have just been waiting for the next....
TheMotleyFool 
0 02.12.17
Better Buy: GlaxoSmithKline plc vs. Pfizer
Better Buy: GlaxoSmithKline plc vs. Pfizer
Big drug companies can add an element of stability to investor portfolios. People get sick and need treatment whether the economy is booming or tanking. And big pharma tends to pay hefty....
TheMotleyFool 
0 30.11.17
The Federal Government Just Broke Its Medical-Marijuana Promise
The Federal Government Just Broke Its Medical-Marijuana Promise
Few if any industries are growing at a quicker and more consistent pace in the U.S. than marijuana. A report released earlier this year by Marijuana Business Daily entitled "Marijuana Business....
TheMotleyFool 
0 26.11.17
Why Marijuana Stock GW Pharmaceuticals Skyrocketed 11% Today
Why Marijuana Stock GW Pharmaceuticals Skyrocketed 11% Today
After the company released updated clinical trial data showing efficacy of its marijuana drug as a monotherapy and improvement from baseline over long-term use, shares of GW....
TheMotleyFool 
0 21.11.17
The 4 Largest Pure-Play Marijuana Stocks
The 4 Largest Pure-Play Marijuana Stocks
Marijuana hasn't come by the nickname "the green rush" by accident. If we take a closer look at the performance of marijuana stocks, most have had investors seeing a lot of green over the trailing....
TheMotleyFool 
0 17.11.17
Here's What Cost GlaxoSmithKline PLC Nearly $10 Billion in Market Cap in October
Here's What Cost GlaxoSmithKline PLC Nearly $10 Billion in Market Cap in October
Shares of U.K.-based Big Pharma giant GlaxoSmithKline (NYSE: GSK) tumbled during the month of October, according to data from S&P Global Market Intelligence, losing nearly $10 billion in....
TheMotleyFool 
0 08.11.17